Home Page

Patient Image Frank Video play icon

Patient Video

Meet Frank

This 60-second video introduces you to Frank, who is 65 years old with advanced atherosclerosis, a prior MI, and type 2 diabetes. He’s also been cheering on his local football team for more than 60 years. Learn how JARDIANCE can help you have the power to add years to Frank’s life, so he can stay in the game.

Watch video
Patient Image Lucille Video play icon

Patient Video

Meet Lucille

Lucille is 68 years old. She has underlying heart failure with prior MI and type 2 diabetes. Managing her conditions is a challenge, but her loving husband and family have supported her every step of the way. Watch this 60-second video to see how prescribing JARDIANCE early can help you keep Lucille home with her family and out of the hospital.

Watch video

Footnotes:

*Adult patients with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke.1,2

†Standard of care included CV medications and glucose-lowering agents given at the discretion of healthcare providers and according to recommendations of local guidelines.1,2

‡CV death was part of the composite primary endpoint, 3-point MACE in the EMPA-REG OUTCOME® trial and 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001). There were no significant differences between the placebo and JARDIANCE groups of nonfatal MI (HR=0.87; 95% CI: 0.70, 1.09; p=0.22) or nonfatal stroke (HR=1.24; 95% CI: 0.92, 1.67; p=0.16). Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME® trial (HR=0.65; 95% CI: 0.50, 0.85).1,2

CAD=coronary artery disease; CI=confidence interval; CV=cardiovascular; HHF=hospitalisation for heart failure; HR=hazard ratio; MACE=major adverse cardiovascular events; MI=myocardial infarction; PAD=peripheral artery disease; RRR=relative risk reduction; T2D=type 2 diabetes.

References:

1.

JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; September 2020.

2.

Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix for certain baseline characteristics.)